Tyra Biosciences, Inc. (TYRA) Earnings Call Transcripts

Tyra Biosciences, Inc.'s Latest Earnings Call - May 13, 2026

In Q1 FY2026, Tyra Biosciences presented a promising outlook driven by its lead drug, [davogratinib], targeting FGFR3 mutations in multiple indications. The company highlighted the potential of this drug in intermediate-risk non-muscle invasive bladder cancer (NMIBC) and upper tract urothelial carcinoma (UTUC), with upcoming data readouts expected in August. Revenue and earnings figures were not disclosed, but management emphasized the significant market opportunities, comparing them to existing blockbuster drugs. Guidance was updated with a focus on the August data readout, which will determine the progression to Phase III trials.

Reported metrics

Guidance from management

Management updated guidance to expect an initial data readout in August for the NMIBC study, which will inform the decision to proceed to Phase III trials.

What management said

Yes, we didn't have any dose reductions or discontinuations at our 40, 60-milligram dose. Now that's not to say that in a large study, we wouldn't expect any in the [indiscernible] study, the [ TAR210 ] Phase II update, the discontinuation rate was about 10%. So we would be looking for low rates of discontinuations or dose reductions.

Yes, there's 80,000 new patients diagnosed with bladder cancer. So the majority of those are going to be in the NMIBC setting [indiscernible] low-risk intermediate risk highest you do the TURBT you're not necessarily going to know precisely what you got. So that's obviously a large amount of new patients every year. But in addition to that 750,000 patients living with cancer and many of those are going to follow on ...

What analysts pressed on

Analysts expressed concerns about the safety profile in an elderly population, particularly regarding diarrhea and ALT/AST levels. They also questioned the market share potential given the existing treatment paradigms.

Main topics on the call

• FGFR3 Inhibitor Potential — Tyra's lead drug, [davogratinib], is positioned as a highly selective FGFR3 inhibitor with potential applications in bladder cancer and skeletal conditions. Management emphasized its potential to address significant unme...
• Intermediate-Risk NMIBC Opportunity — The company highlighted the intermediate-risk NMIBC market, with 35,000 new FGFR3-positive patients annually. Tyra aims to offer a more tolerable oral alternative to existing treatments. "This is actually really comparab...
• Upcoming Data Readout — Tyra plans to release data from its ongoing study in August, which will include efficacy and safety results for [davogratinib] in NMIBC. This readout is critical for advancing to Phase III trials. "This is going to be th...
• UTUC Market Potential — The UTUC indication is described as a rare disease with a high percentage of FGFR3-positive patients. Tyra is optimistic about achieving premium pricing and significant market penetration due to the unmet need. "This cou...

Read the full Tyra Biosciences, Inc. transcript (May 13, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 10 Tyra Biosciences, Inc. earnings call transcripts on record, spanning November 29, 2022 to September 9, 2026. Based on this history, Tyra Biosciences, Inc. reports semi-annually. The most recent call on file is dated September 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

TYRA

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

10

First call

November 29, 2022

Most recent

September 9, 2026

Reporting cadence

semi-annually